Second-line antiretroviral therapy regimen change among adults living with HIV in Amhara region: a multi-centered retrospective follow-up study

Muluneh Alene1*, Tadesse Awoke2, Melaku Kindie Yenit2, Adino Tesfahun Tsegaye2, Leltework Yismaw1 and Reta Yeshambel3

Abstract
Objective: This study was conducted to determine the rate of initial second-line ART regimen change and its predictors among adults living with HIV in Amhara region. A retrospective follow-up study was conducted between February, 2008 and April, 2016 at eight governmental hospitals of Amhara region. Person-times and Cox proportional hazard model were fitted to determine the rate and to identify the significant predictors of second-line treatment regimen change.

Results: A total of 897 records of patients were analyzed. The overall rate of initial second-line drug regimen change was 24.2 per 100 person years. The rate of regimen change was decreased for patients with formal education (HR: 0.77, 95% CI 0.61–0.97), under WHO clinical stage-III (HR: 0.57, 95% CI 0.45–0.73), and WHO clinical stage-IV (HR: 0.64, 95% CI 0.43–0.96). Patients who were taking CPT (HR: 2.05, 95% CI 1.45–2.89) had an increased rate of regimen change. Furthermore, the rate of regimen change was decreased for patients who were switched to second-line treatment due to virological failure (HR: 0.36, 95% CI 0.25–0.53), and due to drug toxicity (HR: 0.48, 95% CI 0.28–0.81). Therefore, addressing significant predictors to maximize the durability on the initial regimen among ART clients is essential.

Keywords: Amhara region, Regimen change, Retrospective study, Second-line

Introduction
Globally, about 21.7 million people living with human immunodeficiency virus (HIV) were receiving antiretroviral therapy (ART) at the end of 2017 [1]. Africa, is the region most affected by the epidemic, and about 60% of people living with HIV were accessing ART at the end of 2017 [1, 2]. In Ethiopia, the coverage of ART among adults has been increased from 4 to 60% between 2005 and 2015 [3]. Accordingly, in Amhara region, about two-third (63.45%) of patients were receiving ART in 2015 [3, 4]. According to the global estimate, about 5.5% of patients were receiving second-line treatment in 2016 worldwide [5]. In sub-Saharan Africa, nearly 2 out of 100 HIV patients switched to second-line ART every year [6]. Patients on second-line treatment accounted for 1.5% of all patients on ART in Ethiopia [3].

Despite ART enables to suppress viral load and restore immune function, the emergency of drug resistance makes a significant challenge to achieve better treatment response [7, 8]. In Ethiopia, discontinuing from ART has been increased, and one out of five patients had discontinued from treatment [9]. Though modifying drug regimen after documenting treatment failure can prevent the worsening of drug resistance [10], the availability of second-line ART regimens are limited in developing countries [11]. In resource-poor countries including Ethiopia, maximal durability of drug regimen with respect to safety and efficacy is crucial [12, 13]. In Ethiopia, between 2012
and 2014 the initial ART regimen was changed for 9.8% and 31.4% of patients respectively [13].

Previous studies reported that drug toxicity, treatment failure, Tuberculosis (TB) treatment and pregnancy were the main reasons of ART regimen change [14, 15]. In Ethiopia, where the options of ART regimens are limited, determining the rates of initial second-line ART regimen change is important for appropriate intervention. Yet little is known on the rate and predictors of initial second-line ART regimen change in Ethiopia, particularly in Amhara region. Thus, this study was conducted to determine the rate and to identify the predictors of initial second-line ART regimen change among adults living with HIV in Amhara region.

Main text

Methods

Study design and setting

A retrospective follow-up study was conducted between February, 2008 and April, 2016 in Amhara region. This study included eight governmental hospitals: namely, University of Gondar teaching and referral hospital, Felege Hiwot referral hospital, Debre Marksos referral hospital, Dessie referral hospital, Debre Tabor hospital, Woldiya hospital, Finote Selam hospital, and Debre Birhan referral hospital. Records of 897 ART clients were analyzed. We excluded patients whose information on the regimen change didn’t documented.

Study variables and data collection procedure

In this study, the outcome variable was time to initial second-line ART drug regimen change. Regimen change is defined as a substitution of at least one drug from the initial second-line ART regimen. Patient’s survival time were measured from the start of second-line ART up to the time of initial drug regimen changed or when patients were censored. Lost to follow-up, dead, transferred, and defaulters were considered as censored. Socio-demographic variables (age, gender, educational status, occupation and functional status), treatment-related variables [TB treatment, isoniazid (INH) and co-trimoxazole preventive therapy (CPT)], body mass index (BMI), CD4 cell count, and WHO clinical stages at switch were analyzed.

The data was collected by trained nurses after organized a standard checklist. Charts were retrieved using patient’s medical record and ART registration numbers found in the database of health facilities. The quality of collected data was assured by using a pretested questionnaire and trained data collectors. Data completeness and consistency was also checked by supervisors on daily bases.

Data analysis

The data were checked for completeness, coded, and entered into EPI-INFO version 7 and analyzed using R statistical software. The follow-up duration for patients who are changing their regimen was calculated from initiation of second-line ART to a substitution of at least one drug from the initial regimen. Similarly, the follow-up duration for clients who didn’t change their regimen (censored) was calculated from the time of initiation of second-line ART until the last visit. Descriptive statistics were computed to summarize the included variables. Person-times contributed by study participants in the follow-up period were performed to measure the rates of regimen change. Furthermore, Kaplan-Meier estimator curves were used to describe the distributions of survival times (Additional file 1: Figure S1). The Cox proportional hazards model was fitted to identify the predictors of regimen change. In Cox proportional hazards model the baseline hazard function doesn’t need to be follow a particular statistical distribution. Variables which have a 95% confidence interval for adjusted HR without including one were considered as significant predictors of initial second-line treatment regimen change.

Results

Characteristics of study participants

A total of 897 records of patients were analyzed. Half (49.9%) of the cohort were male, and more than one-third (35.3%) hadn’t formal education. About half (49.1%) of study participants were started second-line treatment between age of 25–34 years, while 10.3% of the patients started above 45 years old. The majority (86.2%) of the respondents were performed the usual work at the initiation of second-line treatment. Nearly two-third (62.1%) of patients initiated second-line ART below CD4 count of 100 cells/mm³. About one-fourth (22.6%) of cohort were receive INH prophylaxis, while 16.5% of respondents were obtain TB treatment. About half (46.3%) of patients switched to second-line ART due to immunological failure, and 33.7% due to clinical failure. At the time of second-line ART initiation, nearly half (48.3%) of them were under WHO clinical stage-I, 10.5% were under WHO clinical stage-II, and 33.4% were under WHO clinical stage-I classification (Table 1).

Frequency and rates of second-line ART regimen change

Of the total cohort who were changed the drug regimen, about three-quarter (77.80%) and 20.49% of them were changed for one times and two times respectively (Additional file 2: Table S1). In the follow-up period, at least one drug from the initial second-line ART regimens was changed for nearly half [442 (49.3%)] of patients. A total
of 1,828.5 person years were contributed by the study participants. The overall rate of drug regimen change in the study setting was 24.2 per 100 person years, and it was high during the first year of follow-up (23 per 100 person years) (Additional file 3: Table S2).

Predictors of second-line ART regimen change

Educational status, WHO clinical stages at switch, CPT prophylaxis, and the reason for switch to second-line ART were found to be significant predictors of initial second-line ART regimen change (Table 2). This study showed that females had a decreased rate of drug regimen change (Fig. 1). Patients who had formal education (HR: 0.77, 95% CI 0.61–0.97) had a lower rate for regimen change as compared to patients without formal education. The rate of regimen change appeared to be higher for patients taken CPT prophylaxis (HR: 2.05, 95% CI 1.45–2.89) as compared to its counterpart. Patients who were under WHO clinical stage-III (HR: 0.57, 95% CI 0.45–0.73), and under WHO clinical stage-IV (HR: 0.64, 95% CI 0.43–0.96) had a decreased rate of regimen change as compared to patients who were under WHO clinical stage-I classification.

Patients who were switched to second-line treatment due to immunological failure (HR: 0.64, 95% CI 0.52–0.79) had a lower rate for regimen change than patients switched to second-line ART due to clinical failure. Similarly, patients who were switched to second-line ART due to virological failure (HR: 0.36, 95% CI 0.25–0.53) had decreased rate of regimen change as compared to patients switched due to clinical failure. Furthermore, patients who were switched to second-line ART due to drug toxicity (HR: 0.48, 95% CI 0.28–0.81) had a decreased rate of regimen change than patients switched to second-line ART due to clinical failure. Variables like BMI and CD4 cell count at second-line ART initiation didn’t show any significant association with drug regimen change.

Discussion

This study was conducted to determine the rate and to identify the predictors of second-line ART regimen change. During the follow-up period, at least one drug from the initial second-line ART regimens was changed for nearly half (49.3%, 95% CI 46.0–52.6%) of patients. This result is comparable with a study conducted in southwest Ethiopia [14], reported that about 47.7% adults changed their initial regimen. On the contrary, this finding was higher than a study conducted in northwest Ethiopia [16]. The possible explanation for this variation might be due to the difference in the characteristics of study participants [17]. The present study showed that the rate of regimen change was
Table 2 Univariable and multivariable semi-parametric proportional hazard model on predictors with time to initial second-line ART regimen change among adults in Amhara Region (February 2008-April 2016) (n = 897)

| Variables                      | Status  |       | Crude HR (95% CI) | Adjusted HR (95% CI) |
|--------------------------------|---------|-------|-------------------|----------------------|
|                                | Event   | Censored |                  |                      |
| Gender                         | 234     | 215    |                   | Ref                   |
| Female                         | 208     | 240    | 0.78 (0.64 0.94)  | 0.88 (0.71 1.08)     |
| Male                           | 208     | 240    |                   |                      |
| Age                            | 38      | 54     |                   | Ref                   |
| 15–24                          | 222     | 218    | 1.12 (0.79 1.58)  | 1.16 (0.81 1.65)     |
| 25–34                          | 133     | 138    | 0.92 (0.64 1.32)  | 1.03 (0.71 1.50)     |
| ≥ 45                           | 49      | 45     | 1.02 (0.67 1.56)  | 0.89 (0.57 1.38)     |
| BMI                            | 253     | 248    | 1.04 (0.85 1.28)  | 1.06 (0.86 1.32)     |
| < 18.5                         | 150     | 174    | Ref               | Ref                   |
| 18.5–24.99                     | 39      | 33     | 1.05 (0.75 1.48)  | 0.98 (0.69 1.4)      |
| ≥ 25                           | 157     | 160    | Ref               | Ref                   |
| Educational status             | 285     | 295    | 0.82 (0.67 0.99)  | 0.77 (0.61 0.97)*     |
| No formal education            | 188     | 169    | Ref               | Ref                   |
| Formal education               | 132     | 151    | 0.86 (0.69 1.08)  | 1.02 (0.79 1.33)     |
| Occupation                     | 122     | 135    | 0.94 (0.75 1.19)  | 1.08 (0.85 1.38)     |
| WHO clinical stage             | 236     | 197    | Ref               | Ref                   |
| I                              | 42      | 52     | 0.87 (0.63 1.20)  | 0.75 (0.53 1.06)     |
| II                             | 132     | 168    | 0.52 (0.42 0.64)  | 0.57 (0.45 0.73)*     |
| III                            | 32      | 38     | 0.55 (0.38 0.81)  | 0.64 (0.43 0.96)*     |
| IV                             | 37      | 76     | Ref               | Ref                   |
| CPT given                      | 405     | 379    | 2.40 (1.72 3.37)  | 2.05 (1.45 2.89)*     |
| Reason for switch              | 185     | 117    | Ref               | Ref                   |
| Clinical failure               | 203     | 212    | 0.59 (0.48 0.72)  | 0.64 (0.52 0.79)*     |
| Immunological failure          | 37      | 103    | 0.29 (0.20 0.41)  | 0.36 (0.25 0.53)*     |
| Virological failure            | 17      | 23     | 0.43 (0.26 0.71)  | 0.48 (0.28 0.81)*     |
| Drug toxicity                  | 378     | 395    | Ref               | Ref                   |
| Functional status              | 61      | 48     | 1.30 (0.99 1.71)  | 1.26 (0.94 1.69)     |
| Working                        | 3       | 12     | 1.10 (0.35 3.45)  | 0.94 (0.29 2.96)     |
| Ambulatory                     | 330     | 364    | Ref               | Ref                   |
| Bedridden                      | 112     | 91     | 1.06 (0.85 1.31)  | 1.24 (0.99 1.56)     |
| INH given                      | 367     | 382    | Ref               | Ref                   |
| TB treatment                   | 75      | 73     | 0.77 (0.60 0.99)  | 0.99 (0.74 1.35)     |
| CD4 cell count                 | 186     | 154    | Ref               | Ref                   |
| ≥ 100 cells/mm³                | 256     | 301    | 0.79 (0.65 0.96)  | 0.82 (0.67 1.01)     |
| < 100 cells/mm³                | Ref     | Ref    |                   |                      |

Ref. reference category

* 95% confidence interval for significant predictors
higher during the first year of follow-up. It is reasonable that drug adverse effects are high in the first year of follow-up [18]. In this study, the overall rate of initial second-line ART regimen change was 24.2 per 100 person years. This finding is higher than previous studies conducted in Zambia and northwest Ethiopia [16, 19]. Similarly, the incidence rate of regimen change for this study is higher than previous studies conducted in Kenya among first-line ART users [20, 21].

The findings of this study revealed that patients who had formal education had a decreased rate of regimen change as compared to patients without any formal education. The probable reason for this result might be education enable individuals to have better understanding of antiretroviral drug adherence and good nutritional status which in turn reduces the rate of regimen change [22]. However, this finding is contradicted with a study conducted in south west Ethiopia [14] which showed that patients who had above primary level of education had an increased rate of regimen change than those below primary level of education. Probably, this might be due methodological difference between the present and previous study. In this study, clients who were taking CPT prophylaxis had an increased rate of regimen change as compared to patients who were not taking CPT. This might be due to the contradiction of CPT and ART drug regimens.

This study showed that patients who were under WHO clinical stage-III at the time of switch had a decreased rate for regimen change as compared to patients who were under WHO clinical stage-I. In addition, patients who were under WHO clinical stage-IV at switch were less likely for regimen change as compared to patients who were under WHO clinical stage-I.

The results of this study showed that HIV infected patients who were switched to second-line ART due to the reason of immunological failure had a decreased rate of regimen change as compared to patients who were switched to second-line ART due to clinical failure. Furthermore, patients who were switched to second-line ART due to the reason of virological failure had a decreased rate of regimen change than patients who were switched to second-line ART due to clinical failure. Moreover, adults with HIV who were switched to second-line ART due to the reason of drug toxicity had a decreased rate of regimen change as compared to patients who were switched to second-line ART due to clinical failure.

Conclusions
A high rate of initial second-line ART regimen change was observed. The rate of drug regimen change was higher for patients hadn’t formal education, being under WHO clinical stage I, taking cotrimoxazole prophylaxis, and the reason for switch to second-line ART were due to clinical failure. Therefore, addressing significant predictors to maximize the durability on the initial regimen is essential, and sustainable monitoring to reduce the rate of regimen change is also desirable.

Limitations
Though we have done our best to indicate the incidence rate and predictors of regimen change, it is not free from limitations. The retrospective nature of the study limited the inclusion of all possible factors that could affect the rate of regimen change. Variables such as hemoglobin level, nutritional status, and side effects were some of the plausible factors that were not measured in this study.

Additional files

Additional file 1: Figure S1. Kaplan-Meir curve of surviving patients on initial regimens under second-line treatment by gender difference at governmental hospitals of Amhara region (February 2008 to April 2016).

Additional file 2: Table S1. Frequency of regimen change under second-line treatment among adults in Amhara region (February 2008-April 2016) (n=527).

Additional file 3: Table S2. Rates of regimen change in one year interval from second-line treatment among adults in Amhara Region (February 2008-April 2016).
Abbreviations
ART: antiretroviral therapy; CPT: cotrimoxazole preventive therapy; HIV: human immunodeficiency virus; INH: isoniazid; IRB: institutional review board; WHO: World Health Organization; HR: hazard ratio; TB: tuberculosis.

Acknowledgments
We would like to acknowledge the University of Gonder for giving ethical clearance to conduct this research. We would also like to thank all persons participated in this study.

Authors’ contributions
MA, TA, MKY, ATT, LY and RY are involved in the conception, design, data collection, analysis and report writing. MA, TA, MKY, ATT, LY and RY assisted with the design, approved the proposal, and participated in data analysis and manuscript preparation. All authors read and approved the final manuscript.

Funding
There is no funding for this manuscript.

Availability of data and materials
The datasets and materials used in this study are available upon request to the corresponding author.

Ethics approval and consent to participate
The ethical clearance was obtained from the Institutional Review Board (IRB) of the University of Gonder (Ref. No: IPH/2485/2017). Letter of permission was secured from the respective ART clinics of each selected hospitals. Moreover, the confidentiality of information obtained was guaranteed by using code numbers rather than personal identifiers and by keeping the checklist locked. But consent to participate was not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Public Health, Debre Markos University, Debre Markos, Ethiopia. 2 Department of Epidemiology and Biostatistics, University of Gonder, Gondar, Ethiopia. 3 Department of Biology, Mizan-Tepi University, Teppi, Ethiopia.

Received: 6 June 2019 Accepted: 5 July 2019 Published online: 15 July 2019

References
1. World Health Organisation. Antiretroviral therapy (ART) coverage among all age groups. Geneva: WHO, 2017.
2. Wang H, Wolock TM, Carter A, Nguyen G, Kyu HH, Gakidou E, Hay SJ, Mills EJ, Trickey A, Msemwili W, Coates MM. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV. 2016;3(8):e361–87.
3. Assessa Y, Gilsis CF, Lynen L, Williams O, Hill PS, Tolera T, et al. Performance of the antiretroviral treatment program in Ethiopia, 2005–2015: strengths and weaknesses toward ending AIDS. Int J Infect Dis. 2017;60:70–6. https://doi.org/10.1016/j.ijid.2017.05.012.
4. Ethiopian public health institute. HIV related estimates and projections for Ethiopia. Addis Ababa: Ethiopian public health institute; 2017.
5. World Health Organisation. Antiretroviral medicines in low-and middle-income countries: forecasts of global and regional demand for 2014–2018. Geneva: WHO, 2015.
6. Haas AD, Keiser O, Balestree E, Brown S, Bissagnene E, Chimbetete C, et al. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. Lancet HIV. 2015;2:e271–e278.
7. Hamers RL, Wallis CL, Kitto C, Siwale M, Mandalaya K, Conradie F, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011;11:759–9. https://doi.org/10.1016/S1473-3099(11)70149-9.
8. Nansseu JR, Bigna JR. Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new test and treat policy of the World Health Organization? Infect Dis Poverty. 2017;6:1–5. https://doi.org/10.1186/s40249-017-0240-3.
9. Gesessew HA, Ward P, Woldemichael K, Mwanni L. Prevalence, trend and risk factors for antiretroviral therapy discontinuation among HIV-infected adults in Ethiopia in 2003–2015. PLoS ONE. 2017;12(6):e0179533. https://doi.org/10.1371/journal.pone.0179533.
10. Zhou JL, Li P. Deferred modification of antiretroviral regimen following documented treatment failure in Asia results from the TREAT Asia HIV Observational Data base (TAHOD). Ther Res Educ AIDS Train. 2009;11:31–9.
11. Clinton Health Access Initiative. ARV ceiling price list. August, 2013. https://www.clinichealthaccess.org/news-and-information/ARV-Ceiling-Price-List-May-2013.
12. Onoya D, Brennan AT, Berhanu R, Van Der Berg L, Buthelezi T, Fox MP. Changes in second-line regimen durability and continuity of care in relation to national ART guideline changes in South Africa. J Int AIDS Soc. 2016;19(1):1–13.
13. Wubshtet M, Berhane Y, Worku A, Kebede Y, Diro E. High loss to followup and early mortality create substantial reduction in patient retention at antiretroviral treatment program in North-West Ethiopia. ISRN AIDS. 2012;2012. Article number: 721720. https://doi.org/10.5402/2012/721720.
14. Mekonnen E, Workicho A, Hussein N, Feyera T. Reasons and predictors for antiretroviral therapy change among HIV-infected adults at South West Ethiopia. BMC Res Notes. 2018;11:351. https://doi.org/10.1186/s13104-018-3470-y.
15. Gebremedhin LE, Birhane AM. Reasons for anti-retroviral regimen changes in HIV/AIDS patients of Ayder Referral Hospital ART clinic, Mekelle, Ethiopia. Int J Pharma Sci Res. 2014;5(0975–9492):693–700.
16. Anlay DZ, Alemayehu ZA, Dachev BA. Rate of initial highly active anti-retroviral therapy regimen change and its predictors among adult HIV patients at University of Gonder Referral Hospital, Northwest Ethiopia: a retrospective follow up study. AIDS Res Ther. 2016;13:10. https://doi.org/10.1186/s12981-016-0095-x.
17. Melaku Z, Lamb MR, Wang C, Lulsegged S, Gadisa T, Ahmed S, et al. Characteristics and outcomes of adult Ethiopian patients enrolled in HIV care and treatment: a multi-clinic observational study. BMC Public Health. 2015;15:462. https://doi.org/10.1186/s12889-015-1776-4.
18. Hosseinipour MK, Kumwenda J, Wegel R, Brown L, Mzungu J, Khandi B, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010;11(8):510–8. https://doi.org/10.1111/j.1468-1293.2010.00825.x.
19. Habirana R. Incidence and Determinants of Change of Initial HAART Regimen among Outpatient HIV infected Adults at the University Teaching Hospital in Lusaka, Zambia. Lusaka: The University of Zambia Lusaka; 2013.
20. Ndakala FN, Oyugi JO, Oluka MN, Kimani J, Behrens GM. The incidence of first-line antiretroviral treatment changes and related factors among HIV-infected sex workers in Nairobi Kenya. Pan Afr Med J. 2017;28:7. https://doi.org/10.11604/pamj.2017.28.7.10885.
21. Inzaule S, Otieno J, Kalyango J, Nafisa L, Kabugo C, Nalusiba J, et al. Incidence and predictors of first line antiretroviral regimen modification in Western Kenya. PLoS ONE. 2014;9(4):e93106. doi: 10.1371/journal.pone.0093106.
22. Kindie E, Alamrew Anteneh Z, Worku E. Time to development of adverse drug reactions and associated factors among adult HIV positive patients on antiretroviral treatment in Bahir Dar City Northwest Ethiopia. PLoS ONE. 2017;12(12):e0189322. https://doi.org/10.1371/journal.pone.0189322.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.